Company / Cash & Equivalents
Myriad Genetics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$149.6M
FY2025
5-year range
$56.9M / $257.4M
FY2021-FY2025
Trend
+46.1%
vs FY2024
Sector context
#114 of 207
Health Care
What the data says
At $150M, Myriad Genetics, Inc.'s cash & equivalents ranks #114 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $57M in FY2022 to $257M in FY2021.
Based on SEC 10-K filings.
$150M in FY2025 with a 5-year CAGR of -1.8%.
Improved from $132M to $150M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +38.0%
- 5-Year CAGR
- -1.8%
- 10-Year CAGR
- -
Sector benchmark
#114 of 207 in Health CareTop 55% of 207This company $149.6M Sector average $669.5M
▼
-77.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 46.1% year-over-year.
- Ranks #114 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $149.6M | +46.1% |
| FY2024 | $102.4M | -22.5% |
| FY2023 | $132.1M | +132.2% |
| FY2022 | $56.9M | -77.9% |
| FY2021 | $257.4M | +57.2% |
| FY2020 | $163.7M | +75.6% |
| FY2019 | $93.2M | -16.0% |
| FY2018 | $110.9M | +8.3% |
| FY2017 | $102.4M | +49.5% |
| FY2016 | $68.5M | +6.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026